Drug Profile
Research programme: cancer and neurodegenerative disorder therapies - AstraZeneca/University of Cambridge
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator AstraZeneca; University of Cambridge
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Neurodegenerative disorders
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Nov 2018 No recent reports of development identified for research development in Neurodegenerative-disorders in United Kingdom
- 16 Oct 2014 Early research in Cancer in United Kingdom (unspecified route) prior to October 2014